Activation takes a brief, pulls context from Intelligence, runs every output through Content Engine — and hands back versions that are channel-ready, claims-cited, and MLR-risk-scored. The orchestrator layer of the OVYN architecture.
Architecture · Layer 03 · Orchestrator
This is Activation — the surface your team uses. Pulls brand context from Intelligence, scores against Content Engine, deploys to your channels.
The pharma team generates strategic guidance — marketing goal, audience research, ISI cluster, learnings from the last campaign. The agency strategist then takes that guidance and refines it into the actual project brief below. This is the jump-off, not the final brief — your agency's strategist (Suzanne, etc.) reads it, edits it, and hands it to the team. The KPI selection here tunes the engine's reporting downstream so awareness campaigns get awareness KPIs, conversion campaigns get conversion KPIs.
Customizable per client template
Output flows directly into the version generator below. KPI choice locks in the report template — if you picked Awareness, performance reports come back as reach/frequency/share-of-voice; Conversion reverses the lens to qualified-lead funnel.
New brief
Generate versions from a project brief
Drop in your campaign brief, audience, and format mix. The engine writes 8–12 versions, each tagged with a claims-library citation and an internal MLR risk score before MLR sees it.
Campaign · indication
Audience
Angle
Brief copy · what was filmed / what we want said
Format mix · pharma DTC library
Est. runtime ~52 sec✓ Pulling claims library, ISI, OPDP guardrails, last 12 months Veeva performance
Activity
Recent generations
GEN-218 · 12 min ago
12 variants · BRF-2026-04-31
by Demo Viewer
38 s
GEN-217 · 1 hr ago
8 variants · BRF-2026-04-30
by Demo Viewer
26 s
GEN-216 · 2 hrs ago
6 variants · BRF-2026-04-29
by OVYN strategy team
22 s
GEN-215 · Yesterday
4 variants · BRF-2026-04-28
by Demo Viewer
18 s
286 variants generated this month across 9 active campaigns. Equivalent traditional agency creative line: ~$84,000.
Active campaigns
Briefs in flight
AllCompound DT-204PipelineDisease state
BRF-2026-04-31Active
Q2 caregiver awareness · 'When you knew it wasn't a heart attack'
Every brief generates the full pharma format suite — not just social. Email banners (HCP + patient), display banners across IAB sizes, eBlast HTML, IVA frames, detail aids. Each format ships with audience-tuned hook, ISI proximity built in, and an internal MLR risk score.
✉ Email banner · PatientMLR risk · 14
Subject
What if it isn't a heart attack?
Preheader
A guide to rare cardiology indication — and what you can ask your cardiologist.
Compound DT-204 · rilonacept
Rare cardiology indication is rare. It's also frequently mistaken for cardiac events that aren't responding to standard treatment.
Learn the signs →
ISI · Compound DT-204 is contraindicated in patients with active or chronic infections… [Full Important Safety Information auto-injected per audience profile]
✉ Email banner · HCPMLR risk · 11
Subject
RHAPSODY 24-month data · Compound DT-204 in rare cardiology indication
Preheader
Long-term efficacy + durability data — exact stat and footnote pulled from your approved claims library.
Compound DT-204 · rilonacept
The only IL-1 cytokine trap with FDA approval for rare cardiology indication.
Review the data →
ISI · Compound DT-204 is contraindicated in patients with active or chronic infections… [Full Important Safety Information auto-injected per audience profile]
ISI link badge auto-attached · click-out to full prescribing info
Version inspection · BRF-2026-04-31
Social variants from the same brief
01
✓ VoiceMLR risk · 14
Caregiver POV · diagnosis story
Instagram Reel · 30s
She kept saying it wasn't a heart attack. The third ER visit, someone finally listened.
Rare cardiology indication is rare. It's also frequently mistaken for cardiac events that aren't responding to standard treatment. Compound DT-204 is FDA-approved for adults and children 12 and older who keep having flares.
Learn the signs your team should be asking about.
Citation: [Auto-tagged from approved claims library]
02
✓ VoiceMLR risk · 12
Educational · disease state
Static · 1080×1350
Pericarditis that comes back is a different disease.
Rare cardiology indication is driven by IL-1β. Compound DT-204 is the only FDA-approved IL-1 cytokine trap for the condition — trial-cited efficacy data per the approved claims library.
Talk to your cardiologist about Compound DT-204.
Citation: [Auto-tagged from approved claims library]
03
✓ VoiceMLR risk · 24
Cost & access
Carousel · frame 4 of 8
Compound DT-204 cost shouldn't be the reason you stop the next flare.
Most commercially insured patients pay $10 or less per month with the Compound DT-204 Co-Pay program. Government-insured patients have access via the Patient Assistance Foundation.
See if you qualify for support.
FLAG · Fair-balance: ISI block needs to follow on next frame, currently absent
Citation: [Auto-tagged from approved claims library]
Forward thisOne click to the right page for whoever you need to loop in.